Tuesday, 2 June 2009
Friday 29th May 2009 - Crospon, a medical device developer based in Galway, Ireland, today announced it has agreed a worldwide distribution deal for its flagship gastroenterology product, EndoFLIP. The agreement with Dutch company, Medical Measurement Systems, one of the world's leading companies in the development and distribution of medical gastrodiagnostic systems will result in first customer shipments into Europe during the month of June.
Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area.
The EndoFLIP tool which is pending FDA approval was designed by Crospon to provide a more physiologically relevant diagnostic test for gastroesophageal reflux disease (GERD). Chronic GERD is a prevalent disorder reaching epidemic proportions worldwide that manifests itself as severe heartburn caused by stomach acid refluxing up into the oesophagus.
Crospon's development of the EndoFLIP system was recently recognised with the 2009 European Gastroenterology Technology Implementation of the Year Award by Frost & Sullivan.
Announcing the distribution agreement, John O'Dea, CEO, Crospon said, 'Today's announcement is another significant step in the development of both Crospon and EndoFLIP. The international reach which will be provided by Medical Measurement Systems will be crucial to the successful rollout of the EndoFLIP product and we look forward to working with them in the months and years ahead.'
Expanding, O'Dea said, 'The pace of Crospon's growth over the last six months has accelerated. The establishment of our US operation, CE Mark certification and the recent recognition from Frost & Sullivan means that we are well placed for the challenges of going to market.'
Located in Enschede, a major industrial city in the Netherlands, Medical Measurement Systems distribution network spans across 60 countries and during the first six months distribution of the EndoFLIP tool will be particularly targeted towards Gastroenterologists in the EMEA area.
Commenting on the announcement, Arjen de Weerd, CEO, Medical Measurement Systems said, 'EndoFlip is a very promising new product for medical professionals to actually see and therefore better diagnose the function of the Lower Esophageal Sphincter (LES). EndoFlip fits perfectly in our complete range of GI measurement systems to diagnose gastro-esophageal reflux disease (GERD) and motility disorders.'
In January, Crospon announced that its EndoFLIP system had received CE Mark certification from the NSAI (National Standards Authority of Ireland), the Irish notified body in accordance with the European Medical Device Directive. The Company also announced the appointment of Larry Fulton as Vice President of Sales - Americas located at the Crospon's newly established US operation in Carlsbad, California.
Crospon will be exhibiting the EndoFLIP system at Digestive Disease Week in Chicago, Illinois at the end of May. For further information please view www.endoflip.com.